Robert Steiner

Robert D. Steiner, MD, FAAP, FACMG is Editor-in-Chief of Genetics in Medicine (GIM). He is Professor (Clinical) of Pediatrics at the University of Wisconsin (UW) School of Medicine and Public Health, Chief Medical Officer for PreventionGenetics, and geneticist and Medical Director at Marshfield Clinic Health System. After obtaining his MD from UW, he completed a residency in pediatrics at The University of Cincinnati/Cincinnati Children’s Hospital and Medical Center. Following residency, Dr. Steiner trained in medical genetics at The University of Washington/Seattle Children’s Hospital and Regional Medical Center. He is board certified in Pediatrics, Clinical Genetics, and Clinical Biochemical Genetics.

Steiner’s previous academic positions included Executive Director of the Marshfield Clinic Research Institute and Chief Science Officer at Marshfield Clinic, as well as Executive Associate Director of the UW Institute for Clinical and Translational Research. For most of his career, he was a faculty member at Oregon Health & Science University (OHSU), ultimately named Credit Unions for Kids Professor of Pediatric Research, Professor of Pediatrics and Molecular & Medical Genetics, and (tenured) Vice Chair for Research in Pediatrics. Steiner also served as Chief Medical Officer for Acer Therapeutics. Dr. Steiner is an active clinician with specific interests in inherited metabolic diseases, metabolic bone diseases, laboratory testing, and newborn screening. In addition, he is an accomplished researcher, having served as the Principal Investigator for more than a dozen clinical trials and research studies on Smith-Lemli-Opitz Syndrome (SLOS), Osteogenesis Imperfecta, Phenylketonuria, Lysosomal Storage Diseases, and others. Steiner has authored or co-authored over 150 peer-reviewed original research articles as well as more than 80 reviews, book chapters, and letters. He’s also been a longtime reviewer and award-winning editor for a number of journals.

Dr. Steiner is a member of several professional societies, including the American Society of Human Genetics, American College of Medical Genetics and Genomics (ACMG), Society for Inherited Metabolic Disorders, and the Society for the Study of Inborn Errors of Metabolism. He has had numerous appointments on national committees and advisory boards including as a member and treasurer of the ACMG Board of Directors and of the Health Care System Research Network Board of Governors, the Institute of Medicine advisory panel on accelerating rare disease research, serving as Chair of the ACMG working group on Pompe disease, as a Standing and Steering Committee member of the Newborn Screening Translational Research Network, as an NIH Study Section ad hoc member, and as a member of the ACMG Therapeutics Committee. He was a member of the expert panel convened in 2005 by the US Health and Human Services Health Research Services Agency that reviewed the status of newborn screening in the US and recommended expansion of the program to the US Secretary of Health and Human Services.